{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:14:10Z","timestamp":1784207650785,"version":"3.55.0"},"publisher-location":"Cham","reference-count":14,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972966","type":"print"},{"value":"9783031972973","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97297-3_8","type":"book-chapter","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:08:33Z","timestamp":1761325713000},"page":"97-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Raw Material Considerations for the Manufacture of Cell-Based Therapies"],"prefix":"10.1007","author":[{"given":"Jennifer N.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Csontos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"8_CR1","volume-title":"Alliance for regenerative medicine sector snapshot august 2024 \u2013 the emerging value of cell and gene therapy","author":"ARM","year":"2024","unstructured":"ARM. Alliance for regenerative medicine sector snapshot august 2024 \u2013 the emerging value of cell and gene therapy. Alliance for Regenerative Medicine; 2024."},{"issue":"12","key":"8_CR2","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","volume":"1","author":"D Chancellor","year":"2023","unstructured":"Chancellor D, Barrett D, Nguyen-Jatkoe L, Millington S, Eckhardt F. The state of cell and gene therapy in 2023. Mol Ther. 2023;1(12):3376\u201388.","journal-title":"Mol Ther"},{"key":"8_CR3","volume-title":"Guideline on human cell-based medicinal products","author":"EMA","year":"2008","unstructured":"EMA. Guideline on human cell-based medicinal products. European Medicines Agency; 2008."},{"key":"8_CR4","volume-title":"Guideline on the quality of biological active substances and the clinical use of cell therapies","author":"EMA","year":"2021","unstructured":"EMA. Guideline on the quality of biological active substances and the clinical use of cell therapies. European Medicines Agency; 2021."},{"key":"8_CR5","volume-title":"EudraLex. The Rules Governing Medicinal Product in the European Union. Volume 4 \u2013 Good Manufacturing Practice","author":"EMA","year":"2022","unstructured":"EMA. EudraLex. The Rules Governing Medicinal Product in the European Union. Volume 4 \u2013 Good Manufacturing Practice. Annex 1 \u2013 Manufacture of Sterile Medicinal Products; 2022."},{"key":"8_CR6","volume-title":"General Chapter 5.2.12. Raw materials of biological origin for the production of cell-based and gene therapy medicinal products","author":"EP","year":"2015","unstructured":"EP. General Chapter 5.2.12. Raw materials of biological origin for the production of cell-based and gene therapy medicinal products. European Pharmacopoeia Commission; 2015."},{"key":"8_CR7","volume-title":"ICH Q7: good manufacturing practice guide for active pharmaceutical ingredients","author":"ICH","year":"2000","unstructured":"ICH. ICH Q7: good manufacturing practice guide for active pharmaceutical ingredients. International Council for Harmonisation; 2000."},{"key":"8_CR8","volume-title":"ICH Q1A(R2). Stability testing of new drug substances and products","author":"ICH","year":"2003","unstructured":"ICH. ICH Q1A(R2). Stability testing of new drug substances and products. International Council for Harmonisation; 2003."},{"key":"8_CR9","volume-title":"ICH Q5A(R1): viral safety evaluation of biotechnology products derived from cell lines of human or animal origin","author":"ICH","year":"2019","unstructured":"ICH. ICH Q5A(R1): viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. International Council for Harmonisation; 2019."},{"key":"8_CR10","volume-title":"ISO 20399: biotechnology \u2013 ancillary materials present during the production of cellular therapy products and gene therapy products","author":"ISO","year":"2022","unstructured":"ISO. ISO 20399: biotechnology \u2013 ancillary materials present during the production of cellular therapy products and gene therapy products. International Organization for Standardization; 2022."},{"key":"8_CR11","volume-title":"21 CFR Part 210. Current good manufacturing practice in manufacturing processing, packing, or holding of drugs","author":"US FDA","year":"2024","unstructured":"US FDA. 21 CFR Part 210. Current good manufacturing practice in manufacturing processing, packing, or holding of drugs. United States Food and Drug Administration; 2024a."},{"key":"8_CR12","volume-title":"21 CFR Part 211. Current good manufacturing practice for finished pharmaceuticals","author":"US FDA","year":"2024","unstructured":"US FDA. 21 CFR Part 211. Current good manufacturing practice for finished pharmaceuticals. United States Food and Drug Administration; 2024b."},{"key":"8_CR13","volume-title":"Considerations for the use of human and animal-derived materials in the manufacture of cellular and gene therapy and tissue-engineered medical products \u2013 draft guidance for industry","author":"US FDA","year":"2024","unstructured":"US FDA. Considerations for the use of human and animal-derived materials in the manufacture of cellular and gene therapy and tissue-engineered medical products \u2013 draft guidance for industry. United States Food and Drug Administration; 2024c."},{"key":"8_CR14","volume-title":"USP <1043> \u2212 ancillary materials for cell, gene and tissue engineered products","author":"USP","year":"2024","unstructured":"USP. USP <1043> \u2212 ancillary materials for cell, gene and tissue engineered products. United States Pharmacopeia; 2024."}],"container-title":["Advances in Experimental Medicine and Biology","Cell Therapy Manufacturing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97297-3_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:26:17Z","timestamp":1784204777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97297-3_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972966","9783031972973"],"references-count":14,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97297-3_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"25 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}